Acute Kidney InjuryNCT05533606
Risk Factors and Machine Learning Model for Beta-Lactam Drugs Related Acute Kidney Injury
An observational study of Acute Kidney Injury and Beta-Lactam Antibiotic Toxicity (Diagnosis), run by Qianfoshan Hospital at 1 site in China.
Trial summary
Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Acute Kidney Injury, Beta-Lactam Antibiotic Toxicity (Diagnosis)
- What is being tested?
- Beta-Lactam Drugs
- How many people
- 19,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jul 2022to 30 Jun 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The patients were included if received treatment with β-lactam drugs and discharged from the hospital between January 1, 2018 and December 31, 2020
Who may be able to join
- All inpatients who used β-lactam drugs during hospitalization
- Hospital stay ≥ 48h
- Age ≥18 years
- There are two or more blood creatinine tests during hospitalization
Who cannot join
- Hospital stay < 48h
- Age <18 years
- Glomerular filtration rate (GFR)< 30ml/min/1.73m2 within 48 hours after admission
- AKI was diagnosed on admission
- Less than two Scr test results during hospitalization
- The Scr values were always lower than 40 μmol/L during hospitalization
- Cases with incomplete medical history information
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Analysis of Risk Factors of Beta-Lactam Drugs Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model
Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.
- Being tested
- Beta-Lactam Drugs
- Keywords
- Beta-Lactam drugs, Acute kidney injury, Pharmacoepidemiology, Miss diagnosis, Risk factors, Logic regression
- Medical subject headings
- Acute Kidney Injury, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Beta-Lactam DrugsDrug
During hospitalization，patients used Beta-Lactam drugs.
| Study group | Role | What they receive |
|---|---|---|
| AKI Group | Not described Receives: Drug: Beta-Lactam Drugs | |
| Non-AKI Group | Not described Receives: Drug: Beta-Lactam Drugs |
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs
To analyze the incidence of acute kidney injury in hospitalized patients after using β-lactam drugs and to build a prediction model.
Measured: Through study completion，up to half a year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2022
- Study start1 Jul 2022
- Primary completion30 Jun 2023
- Study completion30 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- More trials run by Qianfoshan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 19,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Qianfoshan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiao Li，MD, Qianfoshan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05533606
- Sponsor's protocol ID
- LCYY-LX-20220103
- Status last verified
- Nov 2023
- First submitted
- 2 Sep 2022
- Last updated
- 18 Nov 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Risk Factors of Beta-Lactam Drugs Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model
- ClinicalTrials.gov ID
- NCT05533606
- Acronym / sponsor ID
- LCYY-LX-20220103
- Keywords
- Beta-Lactam drugs, Acute kidney injury, Pharmacoepidemiology, Miss diagnosis, Risk factors, Logic regression
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 19,000 participants (actual)
- Lead sponsor
- Qianfoshan HospitalUniversity, hospital or other
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 30 Jun 2023 (actual)
- Study completion
- 30 Jun 2023 (actual)
- First posted
- 9 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute kidney injury (AKI), also known as acute kidney failure (ARF), is a common and complex kidney disease in clinic and an important factor related to poor prognosis of patients in clinic. In the present study, a single-center retrospective study was conducted in our center. The clinical data of hospitalized patients received β-Lactam drugs from January 2018 to December 2020 was retrospectively analyzed. The multiple logistic regression analysis suggested that complicated with hypertension, anemia, pneumonia, shock, sepsis, heart failure, combined use of proton pump inhibitors (PPI), angiotensin-converting enzyme inhibitor (ACEI), angiotensin Ⅱ receptor antagonist (ARB) were independent risk factors for AKI related to β-Lactam drugs. In clinical practice, patients with acute kidney injury risk factors should be closely monitored for changes in their blood creatinine and urine output to avoid acute kidney injury. For patients who have suffered from acute kidney injury, the cause should be removed in time and corresponding symptomatic treatment should be given.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AKI Group | – | Drug: Beta-Lactam Drugs |
| Non-AKI Group | – | Drug: Beta-Lactam Drugs |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The patients were included if received treatment with β-lactam drugs and discharged from the hospital between January 1, 2018 and December 31, 2020
Key inclusion criteria (4 listed)
- All inpatients who used β-lactam drugs during hospitalization
- Hospital stay ≥ 48h
- Age ≥18 years
- There are two or more blood creatinine tests during hospitalization
Key exclusion criteria (7 listed)
- Hospital stay < 48h
- Age <18 years
- Glomerular filtration rate (GFR)< 30ml/min/1.73m2 within 48 hours after admission
- AKI was diagnosed on admission
- Less than two Scr test results during hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Beta-Lactam DrugsDuring hospitalization，patients used Beta-Lactam drugs. | Drug | AKI Group, Non-AKI Group |
Primary outcome
The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs
Time frame: Through study completion，up to half a year.
To analyze the incidence of acute kidney injury in hospitalized patients after using β-lactam drugs and to build a prediction model.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2023.
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Kidney Injury and Beta-Lactam Antibiotic Toxicity (Diagnosis), run by Qianfoshan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence of acute kidney injury in hospitalized patients treated with β-lactam drugs (time frame: Through study completion，up to half a year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.